Poxvirus Infections - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poxvirus Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Poxvirus Infections - Pipeline Review, H1 2015', provides an overview of the Poxvirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Poxvirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Poxvirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Poxvirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Poxvirus Infections Overview 6
Therapeutics Development 7
Pipeline Products for Poxvirus Infections - Overview 7
Pipeline Products for Poxvirus Infections - Comparative Analysis 8
Poxvirus Infections - Therapeutics under Development by Companies 9
Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes 10
Poxvirus Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Poxvirus Infections - Products under Development by Companies 14
Poxvirus Infections - Products under Investigation by Universities/Institutes 15
Poxvirus Infections - Companies Involved in Therapeutics Development 16
BioApex, s.r.o. 16
China Biologic Products, Inc. 17
SIGA Technologies, Inc. 18
Takeda Pharmaceutical Company Limited 19
Poxvirus Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
4-ThioIDU - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Antibody for Poxvirus Infections - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BA-368 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
modified vaccinia ankara vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibodies for Vaccinia Infection - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule to Inhibit DNA Synthesis for Viral Infections - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit Viral DNA Polymerase for Herpes and Poxvirus Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
tecovirimat - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
varicella hyperimmune globulins - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Poxvirus Infections - Recent Pipeline Updates 42
Poxvirus Infections - Dormant Projects 44
Poxvirus Infections - Product Development Milestones 45
Featured News & Press Releases 45
Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables
Number of Products under Development for Poxvirus Infections, H1 2015 7
Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Poxvirus Infections - Pipeline by BioApex, s.r.o., H1 2015 16
Poxvirus Infections - Pipeline by China Biologic Products, Inc., H1 2015 17
Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H1 2015 18
Poxvirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Poxvirus Infections Therapeutics - Recent Pipeline Updates, H1 2015 42
Poxvirus Infections - Dormant Projects, H1 2015 44